180 Life Sciences Provides Update On Regulatory Approval Process In The UK And U.S. For Dupuytren's Disease Treatment; Continues Consultations With The UK MHRA And Initiates A Type C Meeting Request With the U.S. FDA
Portfolio Pulse from Happy Mohamed
180 Life Sciences Corp. (NASDAQ:ATNF) has submitted a request to the UK's MHRA for a follow up scientific advice meeting to seek guidance on obtaining Conditional Marketing Authorization (CMA) for the use of adalimumab in the treatment of early stage Dupuytren's disease. The company has also initiated a Type C meeting request with the U.S. FDA to seek advice on obtaining US marketing approval. Promising data from a Phase 2b Dupuytren's treatment trial was published in June 2022.
August 04, 2023 | 1:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
180 Life Sciences Corp. is seeking regulatory approval in the UK and US for its Dupuytren's disease treatment. This could potentially open new markets for the company's product.
The company's move to seek regulatory approval in the UK and US indicates its intention to expand the market for its Dupuytren's disease treatment. If successful, this could potentially increase the company's revenues and positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100